> Detailanzeige

Gonzalvo, Jasmine D.; Meredith, Ashley H.; Pastakia, Sonak D.; Peters, Michael; Eberle, Madilyn; Schmelz, Andrew N.; Pence, Lauren; Triboletti, Jessica S.; Walroth, Todd A.

Changes in clinical markers observed from pharmacist-managed cardiovascular risk reduction clinics in federally qualified health centers: A retrospective cohort study

Literatur-
verwaltung

Zur
Merkliste

Lösche von
Merkliste

Per Whatsapp teilen

Schließen

Merkliste



Sie können Bookmarks mittels Listen verwalten, loggen Sie sich dafür bitte in Ihr SLUB Benutzerkonto ein.
  • Medientyp: E-Artikel
  • Titel: Changes in clinical markers observed from pharmacist-managed cardiovascular risk reduction clinics in federally qualified health centers: A retrospective cohort study
  • Beteiligte: Gonzalvo, Jasmine D.; Meredith, Ashley H.; Pastakia, Sonak D.; Peters, Michael; Eberle, Madilyn; Schmelz, Andrew N.; Pence, Lauren; Triboletti, Jessica S.; Walroth, Todd A.
  • Erschienen: Public Library of Science (PLoS), 2023
  • Erschienen in: PLOS ONE
  • Sprache: Englisch
  • DOI: 10.1371/journal.pone.0282940
  • ISSN: 1932-6203
  • Schlagwörter: Multidisciplinary
  • Entstehung:
  • Anmerkungen:
  • Beschreibung: <jats:sec id="sec001"> <jats:title>Background</jats:title> <jats:p>Reductions in hemoglobin A1c (HbA1C) have been associated with improved cardiovascular outcomes and savings in medical expenditures. One public health approach has involved pharmacists within primary care settings. The objective was to assess change in HbA1C from baseline after 3–5 months of follow up in pharmacist-managed cardiovascular risk reduction (CVRR) clinics.</jats:p> </jats:sec> <jats:sec id="sec002"> <jats:title>Methods</jats:title> <jats:p>This retrospective cohort chart review occurred in eight pharmacist-managed CVRR federally qualified health clinics (FQHC) in Indiana, United States. Data were collected from patients seen by a CVRR pharmacist within the timeframe of January 1, 2015 through February 28, 2020. Data collected include: demographic characteristics and clinical markers between baseline and follow-up. HbA1C from baseline after 3 to 5 months was assessed with pared t-tests analysis. Other clinical variables were assessed and additional analysis were performed at 6–8 months. Additional results are reported between 9 months and 36 months of follow up.</jats:p> </jats:sec> <jats:sec id="sec003"> <jats:title>Results</jats:title> <jats:p>The primary outcome evaluation included 445 patients. Over 36 months of evaluation, 3,803 encounters were described. Compared to baseline, HbA1C was reduced by 1.6% (95%CI -1.8, -1.4, <jats:italic>p</jats:italic>&lt;0.01) after 3–5 months of CVRR care. Reductions in HbA1C persisted at 6–8 months with a reduction of 1.8% ([95%CI -2.0, -1.5] <jats:italic>p</jats:italic>&lt;0.01). The follow-up losses were 29.5% at 3–5 months and 93.2% at 33–36 months.</jats:p> </jats:sec> <jats:sec id="sec004"> <jats:title>Conclusions</jats:title> <jats:p>Our study augments the existing literature by demonstrating the health improvement of pharmacist-managed CVRR clinics. The great proportion of loss to follow-up is a limitation of this study to be considered. Additional studies exploring the expansion of similar models may amplify the public health impact of pharmacist-managed CVRR services in primary care sites.</jats:p> </jats:sec>
  • Zugangsstatus: Freier Zugang